Literature DB >> 33754111

Extended Duration Infusion of Hydroxocobalamin for Vasoplegic Rescue in Septic Shock.

Harrison J Gerdes1, Troy G Seelhammer1, Scott Nei2, Juan Diaz Soto1, Christoph G Nabzdyk1.   

Abstract

Nitric oxide (NO) is a gaseous signaling molecule and a key endogenous mediator of vascular tone. Hydroxocobalamin (HCB) affects NO-mediated vasoplegia as (1) a direct inhibitor of nitric oxide synthase (NOS), thereby decreasing its production, and (2) by binding directly to NO and acting as a scavenger. HCB has been increasingly used in the treatment of refractory vasoplegia, particularly in cardiac surgery and liver transplant patients. Sepsis and septic shock are characterized by an increase in inducible NOS expression and activity with excessive NO production, resulting in endothelial dysfunction and profound systemic vasodilation. Therefore, a careful sustained reduction in NO burden represents a potential therapeutic target. Here, we present a case of refractory septic shock, which resolved after an extended duration infusion of high-dose HCB. We hope to foster further exploration regarding the safety, dosing, and efficacy of HCB when administered for vasopressor refractory septic shock.
Copyright © 2021, Gerdes et al.

Entities:  

Keywords:  cyanokit; hcb; hydroxocobalamin; nitric oxide; nos; septic shock; vasoplegia

Year:  2021        PMID: 33754111      PMCID: PMC7971717          DOI: 10.7759/cureus.13388

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  20 in total

1.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

2.  Use of High-Dose Hydroxocobalamin for Septic Shock: A Case Report.

Authors:  Yichun Lin; Trung Q Vu
Journal:  A A Pract       Date:  2019-05-01

3.  Hydroxocobalamin for the treatment of cardiac surgery-associated vasoplegia: a case series.

Authors:  Pranav R Shah; Penny S Reynolds; Nirvik Pal; Daniel Tang; Harry McCarthy; Bruce D Spiess
Journal:  Can J Anaesth       Date:  2017-12-05       Impact factor: 5.063

4.  Nitric oxide scavenging by hydroxocobalamin may account for its hemodynamic profile.

Authors:  Klaus Gerth; Thomas Ehring; Marian Braendle; Pierre Schelling
Journal:  Clin Toxicol (Phila)       Date:  2006       Impact factor: 4.467

Review 5.  The physiology and pathophysiology of the nitric oxide/superoxide system.

Authors:  T Münzel; T Heitzer; D G Harrison
Journal:  Herz       Date:  1997-06       Impact factor: 1.443

Review 6.  Vasoplegia During Cardiopulmonary Bypass: Current Literature and Rescue Therapy Options.

Authors:  Jamel Ortoleva; Alexander Shapeton; Mathew Vanneman; Adam A Dalia
Journal:  J Cardiothorac Vasc Anesth       Date:  2019-12-14       Impact factor: 2.628

7.  Use of Hydroxocobalamin (Vitamin B12a) in Patients With Vasopressor Refractory Hypotension After Cardiopulmonary Bypass: A Case Series.

Authors:  Sarah Armour; Trygve K Armour; William R Joppa; Simon Maltais; James A Nelson; Erica Wittwer
Journal:  Anesth Analg       Date:  2019-07       Impact factor: 5.108

Review 8.  Nitric oxide synthases: regulation and function.

Authors:  Ulrich Förstermann; William C Sessa
Journal:  Eur Heart J       Date:  2011-09-01       Impact factor: 29.983

9.  Effects of hydroxocobalamin and haemoglobin on no-mediated relaxations in the rat anococcygeus muscle.

Authors:  C G Li; M J Rand
Journal:  Clin Exp Pharmacol Physiol       Date:  1993-10       Impact factor: 2.557

10.  Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock.

Authors:  Angel López; Jose Angel Lorente; Jay Steingrub; Jan Bakker; Angela McLuckie; Sheila Willatts; Michael Brockway; Antonio Anzueto; Laurent Holzapfel; Desmond Breen; Michael S Silverman; Jukka Takala; Jill Donaldson; Carl Arneson; Geraldine Grove; Steven Grossman; Robert Grover
Journal:  Crit Care Med       Date:  2004-01       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.